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Abstract
India has compelling need and keen aspirations for indigenous clinical research. Notwithstanding 
this need and previously reported growth the expected expansion of Indian clinical research has 
not materialized. We reviewed the scientific literature, lay press reports, and ClinicalTrials.gov 
data for information and commentary on projections, progress, and impediments associated with 
clinical trials in India. We also propose targeted solutions to identified challenges. The Indian 
clinical trial sector grew by (+) 20.3% CAGR (compound annual growth rate) between 2005 and 
2010 and contracted by (-) 14.6% CAGR between 2010 and 2013. Phase-1 trials grew by (+) 
43.5% CAGR from 2005–2013, phase-2 trials grew by (+) 19.8% CAGR from 2005–2009 and 
contracted by (-) 12.6% CAGR from 2009–2013, and phase-3 trials grew by (+) 13.0% CAGR 
from 2005–2010 and contracted by (-) 28.8% CAGR from 2010–2013. This was associated with a 
slowing of the regulatory approval process, increased media coverage and activist engagement, 
and accelerated development of regulatory guidelines and recuperative initiatives. We propose the 
following as potential targets for restorative interventions:
• Regulatory overhaul (leadership and enforcement of regulations, resolution of ambiguity 
in regulations, staffing, training, guidelines, and ethical principles [e.g., compensation]).
• Education and training of research professionals, clinicians, and regulators.
• Public awareness and empowerment.
After a peak in 2009-2010, the clinical research sector in India appears to be experiencing a 
contraction. There are indications of challenges in regulatory enforcement of guidelines; training 
of clinical research professionals; and awareness, participation, partnership, and the general image 
amongst the non-professional media and public. Preventative and corrective principles and 
interventions are outlined with the goal of realizing the clinical research potential in India.
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Challenges in India's clinical research environment
India's clinical research environment: The promise of an innovative, population-specific 
health care system supported by indigenous, evidence-based medical research is attractive 
for emerging economies such as Brazil, Russia, India, China, and South Africa, each 
presenting with a unique gene pool and health care environment characteristics and needs 
[1-3]. Unlike in the West, clinical research is a relatively recent venture for the Indian 
society. India represents 17.5% of the world's population but conducts only 1.4% of global 
clinical research (calculated for the period of August 7, 2011 to August 6, 2012) [4-6]. In 
India, numerous factors present advantages for home-grown medical research, specifically 
clinical research: English-speaking health care professionals; expert clinicians (including 
returning, Western-trained physicians); economic growth; access to world-class 
technologies; information technology and data management infrastructure; access to large, 
treatment-naïve and ethnically diverse patient populations with diseases of public health 
relevance; competitive operational costs; and internationally harmonized regulations [7]. 
However, these advantages have not translated into the expected growth in clinical trials in 
India.
Growth, stagnation, and decline: clinicaltrials.gov Analysis of Clinical Research in India
Methods—We accessed the ClinicalTrials.gov database on March 18, 2014 (Appendix A6) 
and used the “Advanced Search” feature, with “India” entered into the “Country 1” field, to 
conduct yearly searches (e.g., 01/01/2002 – 12/31/2002). The overall number of reported 
studies was recorded for each year from 2002–2013, and the yearly numbers by phase were 
broken down for 2005–2013 (due to the paucity of data in prior years). Compound annual 
growth rates (CAGRs) were determined using the following formula:
V(t0) : Start Value; V(tn) : Finish Value; tn − t0 : Number of Years
Results
a Indian clinical trial growth trends: There were 2378 trials registered with at least one 
site in India between 2002 and 2013. Only 44 trials were registered in the years 2002–2004, 
and these years were excluded from further analyses. The Indian clinical trial sector grew by 
(+) 20.3% CAGR of new trials between 2005 and 2010, and it contracted by (-) 14.6% 
CAGR between 2010 and 2013 (Figure 1). (The reduction brings 2013 numbers down to 
2007 levels).
When broken down by phase of development (Figure 2), phase-1 trials grew by (+) 43.5% 
CAGR throughout the 2005-2013 period, but inspection of the individual trials revealed that 
these were almost exclusively Indian-based bioavailability/bioequivalence studies, whereas 
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phase-2 and -3 studies were almost exclusively sponsored by international companies. 
Phase-2 trials grew by (+) 19.8% CAGR from 2005–2009 but contracted by (-) 12.6% 
CAGR from 2009–2013. Phase-3 trials grew by (+) 13.0% CAGR from 2005–2010 and 
contracted by (-) 28.8% CAGR from 2010–2013. Phase-4 trials remained at almost the same 
level, about 20-30 per year, throughout the 2005–2013 periods, except for a peak of 43 trials 
in 2009.
b US and Global Clinical Growth Trends: Between 2005 and 2013, global clinical trials 
grew by (+) 5.6% CAGR (from 12,921 to 20,066), and US clinical trials grew by (+) 2.7% 
CAGR (from 6330 to 7823) (Figure 3). In the United States, a flattening of growth was 
observed after 2008.
Recent challenges and negative developments in India's clinical research 
environment
The decline in the number of clinical trials was associated with an increase in reported 
clinical research mishaps [8-11], negative media coverage [8,9,12-16], activist protests 
[1,17-23], stagnation of the regulatory process [12,24,25] and departure of sponsors and 
collaborators [12,26,27].
In the same period there were increased attempts by regulatory [8,11,13,17,24,28-33], 
research professional [1,3,7,32,34-36] and public stakeholders 
[8,9,14,15,17-23,25,37-39,40-44] to understand and correct this reversal of fortunes. These 
events are summarized in Table 1 and described in the remainder of this article.
Regulatory environment in India
There are three regulatory entities and respective guidelines that regulate clinical research in 
India. The main guideline is “Schedule Y” of the Drugs and Cosmetics Rules [43]. It was 
last revised in 2005. The second guideline, “Good Clinical Practices for Clinical Research in 
India” (of the Central Drugs Standard Control Organization) was established in 2002 and 
reflects many of the principles and recommendations of ICH E6 (International Conference 
on Harmonization's Good Clinical Practice guidelines) [44,45]. The third guideline is the 
“Ethical Guidelines for Biomedical Research on Human Participants” (of the Indian Council 
of Medical Research [ICMR]) from 2006 [46]. Overall, these guidelines reflect almost all 
internationally endorsed principles. Some Indian regulatory requirements are progressive in 
comparison to the rest of the world and are more protective of vulnerable populations and 
minorities, such as mandatory registration of all new clinical trials in the Clinical Trials 
Registry of India (as of 2009) [47]; registration of ethics committees; and use of language 
encouraging respect of participants' cultural, educational, and economic backgrounds [33]. 
Yet these regulations have still come under public and activist scrutiny [9,10,13,22,23,39].
The multiplicity and overlapping nature of the regulations (the three aforementioned 
guidelines) and sometimes ambiguous wording represent additional challenges [11,13,48]. 
This results in lengthy turnaround times for clinical trial approvals and under-enforcement 
of quality standards, which are features that have the potential to dissuade foreign sponsors 
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from conducting clinical trials in India and may have contributed to the reduced number of 
clinical trials and departure of international collaborators [26,27,49].
The main challenge facing the Indian regulatory environment, hampered by understaffed 
and under-resourced agencies, is the ability to enforce regulations [11]. The Fifty-Ninth 
Report on the Functioning of the Central Drugs Standard Control Organization provides the 
following details. Regulatory workload is increasing at an annual rate of 20%, but there is no 
corresponding increase in manpower or infrastructure. Nine officers are handling 
approximately 20,000 applications per year. Furthermore, of 327 sanctioned posts, only 124 
are occupied. Approval of new drugs and biologics, for which 1600 applications are 
submitted yearly, is handled by 25 staff and an additional 25 contractual technical staff. 
Media reports of unethical clinical research and activist petitions have led the Indian 
Supreme Court to put clinical research on hold and initiate regulatory overhaul 
[8-10,12,14,15,17,21,23-25,28-32,50].
Required Regulatory Guidelines
There are several areas that require regulatory guidelines to ensure parity with clinical 
research environments in other countries and response to special needs of the Indian 
environment. These include stem-cell, device, phase-0/microdosing, and integrative 
medicine research and compensation for adverse outcomes to participants in clinical trials 
(currently under development).
Science and regulatory challenge example: stem-cell therapy
Stem-cell research offers the potential to bring innovation to local context, make treatments 
more affordable and aiding in economic development. India demonstrates that stem-cell 
research and development is not confined to industrialized countries and has begun to 
harness stem cells to address its own health needs [51]. However, there are considerable 
scientific, operational, and regulatory gaps in stem-cell research in India compared with the 
developed world. India is responding to this challenge in a myriad of ways, including 
through the mushrooming of stem-cell clinics, establishing regulated and organized stem-
cell research units, and creating task forces to establish guidelines and formalize regulation 
of the field.
Science environment: innovation, education, and centers of excellence
While many reviews of clinical research in India highlight the presence of highly skilled 
clinicians, it appears that the same cannot be said about the number of skilled investigators 
or that the building capacity for clinical research is as high of a priority in India as it is in 
other developing nations [34]. Clinical research is not an established health care career 
pathway in India. In the past, much of the clinical research activity was centered on 
development of generic medications rather than innovative therapeutics. There is an 
estimated pool of only 1500 qualified investigators in India, and there is a lack of 
government-accredited clinical-research training institutions, biostatisticians, and 
epidemiologists [7]. There is a need for clinical research centers to set standards of 
excellence, educate, train, and lead the emerging field of clinical research in India [34,51].
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Negative reports in the media and professional press
Although the media have the means and responsibility to disseminate accurate information 
about clinical research and to help promote public awareness and engagement, unfavourable 
and inaccurate depictions abound and may undermine trust, support, participation in, and 
partnership in clinical research (Figure 4) [14,22,36,37,52-56]. For example, MedIndia.com, 
a website that describes itself as “Asia's premier health portal,” has the following quote in 
one of its articles: “…humans are becoming a source of experimental animals and being 
exploited. Due to intensive and strict Animal guidelines using animals in India too has 
become a very [sic] problem, so the drug companies have shifted their trials to humans 
rather [sic] to animals.”[57].
Sometimes reports emphasize only the negative data when both positive and negative data 
are available. For example, in a review of public perceptions of clinical research, 44% of the 
cohort was reported to have an unfavourable impression of pharmaceutical companies, but 
the fact that 47% of the cohort had a favourable impression of pharmaceutical companies 
was not reported [16,58]. Likewise, the report that 39% of the cohort thought 
pharmaceutical companies failed to serve consumers (higher than in 1997 [19%]) did not 
include that 60% thought that pharmaceutical companies did a good job serving their 
consumers (higher than 2004 [44%]) [16,58].
Public/Patient Environment
The Indian public and patients have high stakes in a successful, indigenous clinical research 
environment that could bring about treatments suited to their needs, support an independent 
health care system, and contribute to the country's economic growth. Patient advocacy 
groups in particular have made significant contributions to clinical research in other 
countries [18-20]. In addition, a lack of knowledge about, awareness of, and participation in 
clinical research can have negative implications and lead to vulnerability to exploitation 
and/or perceptions of exploitation, reduced participation in clinical research, and impaired 
enforcement of standards of clinical trials [18,36-38].
Impact of Challenges and Deficiencies
It is likely that, faced with increasing regulatory turnaround timelines and increasing reports 
of incidents of unethical conduct of clinical research that are amplified and sensationalized 
by the media, sponsors are shying away from conducting research in India [9,22,27]. 
International companies are going elsewhere, and even Indian developers of new 
therapeutics are conducting their research outside of India [26]. And possibly, with 
inadequate resources to enforce regulations, the only recourse regulators have is to limit 
approvals and maintain a situation that discourages sponsors and operators from conducting 
research altogether [13,17,24].
Discussion
Our analyses show that after a peek in 2009-2010, clinical trials in India have experienced a 
decline, while global clinical trials continued to experience growth. We have identified a 
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series of negative regulatory, professional, and public developments in the clinical trial 
sector in India that occurred during this same period (Table 1 and Figure 4). Although 
definitive causality cannot be established between these developments and trial growth 
trends, it is arguable that reversal of these negative developments could facilitate growth of 
the clinical trial sector in India. We propose several preventative and corrective measures 
that we believe are needed to realize the full potential of clinical research in India.
Proposed Solutions
We propose the following comprehensive approach to addresses each of the perceived 
challenges and each of the concerned stakeholders:
• Develop a robust regulatory process with emphasis on expertise, training, 
enforcement, and availability.
• Employ complementary self-regulation activities by industry and relevant 
professional research organizations.
• Develop accreditation programs for research operators and ethics committees.
• Develop quality education and training programs for research professionals and 
clinicians.
• Involve journal editors and peer reviewers.
• Develop awareness programs for patients, the public, and the media providing 
information about clinical research and empowering and encouraging participation 
(principles of autonomy, societal consent, community relevance, and shared 
responsibility).
• Encourage proactive (rather than reactive) non-professional sector involvement in 
the dissemination and enforcement of clinical research standards.
Similarly, in 2004 Maggon [49,59] proposed the following recommendations for the conduct 
of clinical research in India:
• Ensure that all patients are informed about their rights, obligations, and risks in 
their native languages.
• Avoid commercial institutional review boards/ethics review committees.
• Never perform a study in India that would not be approved in in the United States 
or Europe.
• Ensure proper spacing of patients for safety, and avoid enrollment of large number 
of patients within a short period of time.
• Arrange for provision of medication to responding patients for a certain period after 
termination of the trial.
• Set up independent data monitoring and safety boards for large-scale studies.
• Organize Good Clinical Practice training courses, investigator meetings, and 
protocol and case report form trainings.
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Several progressive and unique regulatory initiatives—including clinical research 
organization legislation, registration of ethics committees [29], compensation legislation 
[17,28,30], pharmacovigilance, certification of research sites, and a clinical research ethics 
bill—are underway or in advanced stages of planning in India [7]. Increased interaction 
between regulators and sponsors is encouraged, especially in sensitive developmental 
milestones. Increased interaction between regulators and educators/trainers is also 
encouraged to ensure alignment with regulatory vision, policy, and guidelines and to 
facilitate enforcement of regulations.
Complementary Self-Regulation Activities by Industry
Indian regulatory authorities are in the process of building the infrastructure, resources, and 
expertise required for proper monitoring of clinical trials and enforcement of regulations. 
However, there remains a need for laws on compensation, censure of defaulters, and 
declaration of conflicts of interest by investigators and ethics committee members.
Developing regulations is a slow and evolving process; meanwhile, the clinical research 
industry could engage in activities utilizing its expertise, resources, and access to sites and 
investigators, such as:
• Ensuring selection of sites with trained investigators and accredited ethics 
committees.
• Educating and training clinical research operators, investigators, and ethics 
committee members.
• Encouraging video and audio recording of the volunteer enrolment process and 
other means of ensuring study participants are adequately informed.
• Ensuring adequate compensation for the trial participants.
• Enhancing public awareness, knowledge, and engagement in clinical research.
• Encouraging and supporting clinical site and ethics committee accreditation.
• Conducting quality audits for all types of clinical trials, not only the regulatory 
critical ones.
• Ensuring proper declaration of conflicts of interest by clinical research operators 
and investigators.
• Establishing and/or supporting a unified database of study volunteers to avoid 
cross-participation.
Accreditation Programs for Research Operators and Ethics Committees
Programs such as the Association for the Accreditation of Human Research Protection 
Programs (AAHRPP), Forum for Ethical Review Committees in Asian and the Western 
Pacific (FERCAP), and Strategic Initiative for Developing Capacity in Ethical Review 
(SIDCER) of the ICMR are beginning to take on the role of accrediting and training ethics 
committees in India, but these changes are yet preliminary and purely voluntary [60-62]. A 
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training and accreditation process that is transparent and mandatory will help raise the 
ethical review process to a much higher benchmark and create public faith in the processes 
of clinical research. The authors opine that independent ethics committees with no 
institutional affiliations must mandatorily undergo a continuous accreditation to minimize 
fly-by-night operators.
Education Training and Dissemination of Clinical Research Information
Clinical research education is already a part of clinical training in medical colleges, but 
experienced mentors need to be involved in the process. The rigor of research work and the 
importance of adhering to standards and guidelines must be emphasized early during 
training. A closely tied working and learning environment, collaboration projects, and 
programs involving both academia (e.g., medical, science, and biotechnology schools) and 
industry will enhance indigenous research. Also, minimizing red tape in the research 
processes is critical in the academic environment so that collaboration with scientists outside 
academia is seamless and enhances the development of indigenous intellectual property. In 
addition, exposure of Indian academia (and not just that of premier institutions) to the 
international research environment is critical so that the growth of research in India does not 
take place in silos. Finally, learning about and teaching of clinical research needs to be a 
continuous process, with CRE (continuing research education) being as important as CME 
(continuing medical education) programs. CRE should be made mandatory in medical 
schools and in tertiary care and research centres.
Journal Editors and Peer Reviewers
Journal editors also have a role in protecting the rights of research participants and 
disseminating quality research by ensuring publications conform to methodological and 
ethical principles and are transparent to professionals and the general public [35]. By 
gatekeeping the type of research that is published, journal editors and peer reviewers have 
the capability and obligation to improve the quality of conduct and reporting of clinical 
research.
Patient Advocacy, Non-Governmental Organizations, and the Public at Large: Empowering 
and Informing
The non-professional public—including patient advocacy groups, research activists, 
ethicists, non-governmental organizations, and the media—have an important role in clinical 
research as well. An empowered and informed public will actualize rights and obligations 
relevant to clinical research [37,38]. It will actively partner in the guidance of the sector in 
the following ways: identifying the vulnerability of sensitive groups; accessing resources; 
engaging in official policy-making; providing feedback to research sponsors, operators, and 
regulators about the values and preferences that are important to the non-professional public; 
reporting on the quality of research and enforcement of regulatory and ethical principles; 
and bringing to the attention of policy-makers any meaningful deviations, and thus helping 
monitor and oversee the clinical research sector and enforce regulatory guidelines and 
methodological standards. Important topics of education include:
• The process of clinical research and its role in medical progress.
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• The rights of participants.
• Compensation, including the differences between treatment-and illness-derived 
adverse events.
• Confidentiality
Having adequate information about and knowledge of clinical research is essential for the 
proper function and partnership of all stakeholders involved in clinical research, professional 
and non-professional alike. Empowered public and patient sectors [18] (through advocacy 
groups) can contribute to recruitment efforts, sponsorship of research, and even 
establishment of research networks and competitive grant programs [19,38]. A recent survey 
of 201 genetic disease advocacy organizations reported 91% assisting in study recruitment, 
75% collecting data, 60% providing financial support to researchers, and 56% assisting with 
study design [19]. Some have suggested that public and patient participation in clinical 
research implies a right to ownership of research data [38].
Considering India's expanding clinical research environment and the specific cultural 
challenges that face the conduct of clinical research in India, Mahaluxmivala has expressed 
an urgent need for an all-inclusive program and argues in favour of widespread and 
comprehensive Good Clinical Practice compliance [22]. Another element of the solution is 
educating and engaging the public in clinical research. This is being gradually realized by 
regulators, industry, and academia. According to the National Institutes of Health Director's 
Council of Public Representatives [63], it is believed that public understanding of research 
could contribute to earning public trust in the research enterprise and in the observance of 
human-protection measures in clinical research (Figure 4). An informed public could help 
monitor quality and ethics of clinical trials [21,23]. Feedback could be provided on 
parameters that are of value to clinical trial participants and patients—the ultimate recipients 
of clinical research products.
The public needs to understand that new, safe, and effective drugs to treat illnesses and 
address unmet health care needs can be produced only after clinical trials are conducted in 
humans [64]. Individuals who have participated in clinical research studies and are familiar 
with the conduct of clinical trials appear to have more positive perceptions of clinical 
research than do those of the general public [65], which again advocates for a more-
informed public (one that may be more likely to endorse and partner in clinical research).
It is believed that participant protection in clinical research can be enhanced not only 
through adequate investigator technical and ethical knowledge, but also by increasing public 
awareness of relevant clinical research information [22]. Shah and Garg [20] have identified 
increasing awareness of clinical research as one of the key roles of patient advocacy groups. 
Also, Dr. Surinder Singh, the former Drug Controller General of India (DCGI), stated that 
the regulatory bodies in India are trying to generate awareness among patients regarding 
their rights as they pertain to clinical research, thus taking part in empowering prospective 
study participants to seek and enhance their knowledge and awareness of clinical research. 
Since India stands to benefit from these trials by much-needed investment into health care 
and access to beneficial drugs, there is an urgent need to create an agreeable environment by 
raising awareness and ensuring ethical clinical practice [17,37]. Educating the public on 
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research and development, the inevitability and risks of human experimentation, and the 
promise of safe and effective new treatments for unmet health care needs would better 
position stakeholders to evaluate clinical research and become active partners in the process 
[64].
Conclusions
A sharp decline in clinical trial activity in India since 2009–2010 has been associated with 
reports of ethical improprieties, activist protests, and departure of international collaborators. 
Strong responses from regulators, research professionals, and the public have led to 
exploration of the causes and proposal of solutions to this downward trend. Although 
causality is difficult to establish, the main concerns appear to be related to enforcement of 
clinical trial standards, community awareness, and engagement of patients and the public in 
the clinical-trial process. Regardless of the causes, all stakeholders seem to agree that the 
key goals are protection of human research participants and generation of high-quality 
research results so India can respond to the need and realize the potential for indigenous, 
original, and high-quality clinical research.
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Indian clinical trials from ClinicalTrials.gov: all registered trials (2005–2013). CAGR, 
compound annual growth rate.
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Indian clinical trials from ClinicalTrials.gov: trials by phase (2005–2013).
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Global and US total clinical trials (2005–2013).
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Indian public perception of clinical research: government, industry, academia, and hospitals. 
Adapted from PARTAKE Survey of Public Knowledge and Perceptions of Clinical 
Research in India [37].
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Table 1
India clinical research environment: challenges and proposed solutions.
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• Protection of 
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staff and resources
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regulatory staff
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1 Education and 
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1 Clinical research as 
part of medical 
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proper 
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regulatory 
authorities
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of clinical 
research and 










Public and patients are:
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accurate 
information about 
















































2 Engagement of 
patient/public 
representatives in 
the research process 
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Burt et al. Page 19
Domains Challenges Characteristics of the Desired Research Environment Proposed Solutions
communal research 
policies) [38]
CRO: Clinical Research Organization; CREATE: Continuous Research Education and Training Exercises; NGO: Non-Governmental Organization; 
PARTAKE: Public Awareness of Research for Therapeutic Advancements through Knowledge and Empowerment.
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